gamma-Secretase is an aspartyl protease that cleaves multiple substrates including the amyloid precursor protein (APP) and the Notch proteins. Abnormal proteolysis of APP is involved in the pathogenesis of Alzheimer's disease (AD) and overactive Notch signaling plays an oncogenic role in a variety of cancers. gamma-Secretase has emerged as a promising target for drug development in the treatment of AD and cancer. Assays with increased capacity for high-throughput screening would allow for quicker screening of chemical libraries and facilitate inhibitor development. We have developed a homogeneous time-resolved fluorescence (HTRF)-based assay that makes use of a novel biotinylated recombinant APP substrate and solubilized membrane preparation as the source of the gamma-secretase enzyme. The assay was miniaturized to a 1536-well format and validated in a pilot screen against a library of approximately 3,000 compounds. The overall assay performance was robust due to a calculated Z' factor of 0.74 and its demonstrated ability to identify known gamma-secretase inhibitors such as pepstatin A. This validated assay can readily be used for primary screening against large chemical libraries searching for novel inhibitors of gamma-secretase activity that may represent potential therapeutics for AD and a variety of neoplasms.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096545 | PMC |
| http://dx.doi.org/10.1089/adt.2009.0202 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of a time-resolved fluorescence resonance energy transfer ultra-high throughput screening assay targeting SYK and FCER1G interaction.
SLAS Discov
September 2024
Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, Georgia, USA; Emory Chemical Biology Discovery Center, Emory University School of Medicine, Atlanta, Georgia, USA.
The spleen tyrosine kinase (SYK) and high affinity immunoglobulin epsilon receptor subunit gamma (FCER1G) interaction has a major role in the normal innate and adaptive immune responses, but dysregulation of this interaction is implicated in several human diseases, including autoimmune disorders, hematological malignancies, and Alzheimer's Disease. Development of small molecule chemical probes could aid in studying this pathway both in normal and aberrant contexts. Herein, we describe the miniaturization of a time-resolved fluorescence resonance energy transfer (TR-FRET) assay to measure the interaction between SYK and FCER1G in a 1536-well ultrahigh throughput screening (uHTS) format.
View Article and Find Full Text PDFSmall-Molecule Disruptors of the Interaction between Calcium- and Integrin-Binding Protein 1 and Integrin αβ as Novel Antiplatelet Agents.
ACS Pharmacol Transl Sci
July 2024
Cardeza Center for Hemostasis, Thrombosis, and Vascular Biology, Cardeza Foundation for Hematologic Research, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, United States.
Thrombosis, a key factor in most cardiovascular diseases, is a major contributor to human mortality. Existing antithrombotic agents carry a risk of bleeding. Consequently, there is a keen interest in discovering innovative antithrombotic agents that can prevent thrombosis without negatively impacting hemostasis.
View Article and Find Full Text PDFDevelopment of a Time-Resolved Fluorescence Resonance Energy Transfer ultra-high throughput screening assay for targeting SYK and FCER1G interaction.
bioRxiv
June 2024
Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, Georgia, USA.
Article Synopsis
- The SYK and FCER1G proteins work together in the immune system, but problems with their interaction can lead to diseases like autoimmune issues and Alzheimer's.
- Scientists developed a special test to measure how these proteins interact, making it easier to test lots of different compounds at once.
- They found that a compound called hematoxylin can stop the interaction between SYK and FCER1G, which is exciting because it could help in finding new treatments.
High-throughput screening of compounds targeting RNA editing in Trypanosoma brucei: Novel molecular scaffolds with broad trypanocidal effects.
Biochem Pharmacol
January 2024
Institute of Parasitology, McGill University, Ste. Anne de Bellevue, Quebec H9X 3V9, Canada; Department of Biochemistry, McGill University, Montreal, Quebec H3G 1Y6, Canada. Electronic address:
Mitochondrial uridine insertion/deletion RNA editing, catalyzed by a multiprotein complex (editosome), is essential for gene expression in trypanosomes and Leishmania parasites. As this process is absent in the human host, a drug targeting this mechanism promises high selectivity and reduced toxicity. Here, we successfully miniaturized our FRET-based full-round RNA editing assay, which replicates the complete RNA editing process, adapting it into a 1536-well format.
View Article and Find Full Text PDFHigh-throughput screening of BAM inhibitors in native membrane environment.
Nat Commun
September 2023
Biozentrum, University of Basel, Spitalstrasse 41, 4056, Basel, Switzerland.
Article Synopsis
- The study presents a novel high-throughput functional assay for BAM, a crucial target for new antibiotics in Gram-negative bacteria, using outer membrane vesicles (OMVs) in native membrane conditions.
- The assay demonstrated that the antibiotic darobactin was significantly more effective in OMVs compared to synthetic membranes, emphasizing the importance of using natural environments for drug testing.
- This OMV-based approach allows for miniaturization to 1536-well plates and scalability with large fermentation processes, facilitating extensive screening of commercial compound libraries for antibiotic discovery.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!